Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV000988964 | SCV001138916 | pathogenic | Charlevoix-Saguenay spastic ataxia | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001858698 | SCV002238225 | pathogenic | Spastic paraplegia | 2021-08-29 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the SACS protein in which other variant(s) (p.Asn4549Asp) have been determined to be pathogenic (PMID: 15156359, 21507954). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 802912). This variant has not been reported in the literature in individuals affected with SACS-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Gln3981*) in the SACS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 599 amino acid(s) of the SACS protein. |